Background-Experimental autoimmune myocarditis (EAM), a mouse model of post-infectious cardiomyopathy, reflects mechanisms of inflammatory cardiomyopathy in humans. EAM is characterized by an infiltration of inflammatory cells into the myocardium that can be followed by myocyte fibrosis, edema, and necrosis, leading to ventricular wall dysfunction and heart failure. Different data indicate that CD69 exerts an important immunoregulatory effect in vivo. However, the possible role of CD69 in autoimmune myocarditis has not been studied. Methods and Results-We have explored the role of the leukocyte regulatory molecule CD69 in the inflammation that leads to cardiac dysfunction after myocardial injury in EAM. We have found that after induction of EAM, the draining lymph nodes from CD69-deficient mice developed an exacerbated Th17 inflammatory response, resulting in increases in the numbers of infiltrating leukocytes in the myocardium. In the chronic phase of EAM, transthoracic echocardiography revealed a significantly reduced left ventricular fractional shortening and a decreased ejection fraction in CD69-deficient mice, indicative of an impaired cardiac contractility. This condition was accompanied by a greater extent of myocardial fibrosis, an elevated number of sinus pauses on ECG, and an enhanced ratio of heart weight to body weight in CD69 Ϫ/Ϫ mice. Moreover, both bone marrow transplantation and adoptive transfer of Th17 cells isolated from immunized CD69
M yocarditis and subsequent dilated cardiomyopathy (DCM) are major causes of heart failure in young patients. 1 This condition is characterized by infiltration of inflammatory cells into the myocardium with consequent loss of myocytes and development of fibrosis and necrosis. 2 In a significant fraction of patients, the loss of cardiomyocytes leads to ventricular remodeling, permanent ventricular wall dysfunction, DCM, heart failure, and/or arrhythmias. Myocarditis is induced by a variety of agents, including genetic susceptibility, toxins, viruses, bacteria, and parasites. 3, 4 In addition, myocardial injury can induce an autoimmune response to heart tissue, which has an important role in the pathogenesis of myocarditis and DCM. [5] [6] [7] Experimental autoimmune myocarditis (EAM) is a mouse model of postinfectious myocarditis that can be induced in susceptible mouse strains by immunization with cardiac ␣-myosin heavy chain (MyHC-␣)-derived peptides or by injection of activated MyHC-␣-loaded dendritic cells. 8 -10 In this regard, it has been shown that EAM is a CD4 ϩ T-cell-mediated disease and its development depends critically on the interleukin (IL)-23-STAT4 axis, promoting the expansion of an autoreactive CD4 ϩ T-cell subset characterized by IL-17 production. [11] [12] [13] Mice lacking T-bet, a T-box transcription factor essential for Th1 lineage differentiation, develop a severe form of EAM with increased IL-17 release from heartinfiltrating cells. 12 Accordingly, interferon-␥ (IFN-␥) receptor Ϫ/Ϫ and IFN-␥ Ϫ/Ϫ mice also show an exacerbated and progressive course of disease. 14 -16 These findings further support the notion that IL-17 directly accounts for disease development and point to a negative regulatory role of IFN-␥ and Th1 differentiation in the EAM model. Recent data demonstrate that IFN-␥ is required for the optimal activation and maturation of monocytes and macrophages but that IFN-␥ simultaneously limits the expansion of activated T cells by inducing the release of nitric oxide, thus providing protection from exaggerated or even autoaggresive T-cell responses. 17 
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CD69 is a C-type lectin disulfide-linked homodimer and a member of the natural killer receptor family. Its genes are located in a conserved genomic region known as the natural killer gene cluster on mouse chromosome 6 and human chromosome 12. 18 -21 In vitro CD69 is expressed early by most leukocytes upon activation and in vivo is detected in chronic inflammatory cell infiltrates. 22, 23 Several studies with CD69-deficient mice have shown that CD69 has an immunoregulatory role. 24 Thus, in the absence of CD69, mice show an enhanced antitumor activity and develop an exacerbated form of collagen-induced arthritis. 25 In contrast, the absence of CD69 does not affect neutrophil responses in models of neutrophil-dependent acute inflammatory responses. 26 Given that Th17 lymphocytes are the main mediators of collageninduced arthritis, 27 we have hypothesized that CD69 would be a significant negative regulator of EAM, another condition mediated by Th17 cells. Our findings demonstrate that CD69 acts as a brake on Th17-mediated inflammatory responses in myocardial tissue.
Methods

Mice
CD69-deficient mice were generated in the 129-Sv background as described 28 and were backcrossed to BALB/c for Ͼ12 generations. CD69
Ϫ/Ϫ and control mice used for experiments were 8-to 12-weekold females and were either littermates or age-matched offspring of these littermates in the BALB/c background. All mice were maintained and used under pathogen-free conditions. All animal procedures were approved by the ethics committee of the Universidad Autónoma de Madrid and were conducted in accordance with institutional guidelines that comply with the National Institutes of Health's Guide for the Care and Use of Laboratory Animals. 
Induction of EAM
CD69
Ϫ/Ϫ and control mice were immunized subcutaneously on days 0 and 7 with 100 g/0.2 mL MyHC-␣ peptide (MyHC-␣614 -629 ) Ac-RSLKLMATLFSTYASADR-OH emulsified 1:1 in PBS/complete Freund adjuvant (1 mg/mL; H37Ra; Difco Laboratories, Detroit, Mich). The acute phase of EAM was analyzed on day 21; the chronic phase was analyzed between days 58 and 61.
Isolation of Heart-Infiltrating Cells
Mice were anesthetized, the chest cavity was opened, and the root of the aorta was exposed and cannulated with a 23-gauge needle connected to a peristaltic pump. The heart was perfused at a constant flow of 10 mL/min with PBS for 3 minutes and then digested by perfusion with collagenase II (0.5 mg/mL; Sigma-Aldrich) and protease XIV (0.5 mg/mL; Sigma-Aldrich) in PBS at a constant flow of 1.1 mL/min for 7 minutes at 37°C. 29, 30 The heart was then removed and minced, and the cell suspension was sequentially filtered through 70-, 40-, and 15-m strainers (BD Falcon, Miltenyi Biotec, and Sefar, respectively). After 2 washes with PBS/EDTA/ BSA, heart-infiltrating leukocytes were isolated by Ficoll-Isopaque (densityϭ1.121 g/mL) gradient centrifugation.
Ex Vivo Culture and Analysis of Cytokine Production
Lymph node cells and splenocytes from immunized mice were isolated and restimulated with 10 g/mL MyHC-␣ peptide for 20 and 48 hours. Production of inflammatory cytokines was quantified with flow cytomix beads (Bender MedSystems). Intracellular cytokines produced by CD4 ϩ T cells were measured after exposure of cultures to MyHC-␣ for 72 hours.
Adoptive Transfer Experiments
Wild-type (WT) and CD69 Ϫ/Ϫ mice were immunized as for EAM induction, and axillary-draining lymph nodes were removed at day 10. CD4 ϩ T cells were isolated with antibody-coupled paramagnetic beads (Miltenyi). In vitro differentiation toward Th17 was done by culture for 5 days with ␥-irradiated (30 Gy) antigen-presenting cells, MyHC-␣ peptide (50 g/mL), anti-IFN-␥ (4 g/mL), anti-IL-4 (4 g/mL), recombinant mouse IL-6 (10 ng/mL), recombinant mouse IL-23 (10 ng/mL), and recombinant human transforming growth factor-␤1 (5 ng/mL). Th17-like cells (8ϫ10 6 ) were collected, washed, and injected intravenously into sublethally ␥-irradiated (6 Gy) WT and CD69 Ϫ/Ϫ recipient mice. Animals were monitored by transthoracic echocardiography before and after adoptive transfer to evaluate the evolution of the disease. Mice were killed at day 12 after transfer, and heart infiltrates were analyzed by fluorescence-activated cell sorter.
Chimeric Mice
Ten-to 12-week-old CD69 ϩ/ϩ and CD69 Ϫ/Ϫ female mice were lethally ␥-irradiated with 2 doses of 6.5 Gy and transplanted with a mixture of 4ϫ10 6 bone marrow (BM) cells from RAG2 Ϫ/Ϫ and CD69 Ϫ/Ϫ or RAG2 Ϫ/Ϫ and WT mice in a proportion of 3:1 respectively. The reconstituted mice were subsequently analyzed 21 days after immunization with the MyHC-␣ peptide for their susceptibility to EAM. 
Statistical Analysis
Experiments were performed by using a randomized complete block design (4 levels of treatment at 3 different times) or under a complete randomized design. Four or 5 independent replicates for each experimental condition were obtained as indicated. To determine significant differences (PϽ0.05), data were analyzed by 2-way ANOVA, 1-way ANOVA followed by Bonferroni posthoc multiplecomparisons test, or paired or Student t test. When data did not show normal distribution, they were analyzed by the 2-tailed MannWhitney U test. Analysis was performed by with GraphPad Instat version 3.0 software.
Results
Induction of EAM Produces an Enhanced Th17 Inflammatory Response in the Lymphoid Organs of CD69-Deficient Mice
After the induction of EAM as described previously, 31 the immune response in the acute phase was characterized in WT and CD69
Ϫ/Ϫ mice. We detected that the axillary-draining lymph nodes and spleens of CD69 Ϫ/Ϫ EAM mice had significantly higher levels of activated/memory (CD44 We then assessed whether CD69 affects the cytokine secretion pattern in EAM. We found that IL-17 was the major cytokine produced by lymph node cells from EAM mice and that CD69
Ϫ/Ϫ cell cultures showed significantly higher levels of this cytokine than controls ( Figure 1B 
CD69 Deficiency Increases the Inflammatory Immune Response in Heart Myocardium
Analysis of CD45 ϩ infiltrating cells from the myocardium of WT EAM mice showed a significant increase in CD69 ϩ leukocytes compared with PBS-injected controls (Figure 2A and 2B). The number of CD45 ϩ cells in CD69 Ϫ/Ϫ EAM hearts was 2-fold greater than in immunized WT mice ( Figure  2A ). Phenotypic characterization of the subsets of heartinfiltrating leukocytes revealed a significant increase in neutrophils (CD11b ϩ Gr-1 high ) and macrophages (CD11b ϩ F4/ 80 ϩ ) in the inflammatory cell infiltrate of CD69 Ϫ/Ϫ EAM mice ( Figure 2C and 2D) , indicating greater disease severity. 29 However, no significant differences were detected in the percentages of CD4 ϩ or CD8 ϩ T lymphocytes or dendritic cells (CD11b low CD11c ϩ ; Figure 2E and 2F). Cardiac inflammation was further characterized by hematoxylin and eosin staining of ventricular sections in the acute phase of EAM. These studies revealed larger areas occupied by heart-infiltrating cells in the myocardium of CD69 Ϫ/Ϫ mice ( Figure 3A) . Quantitative histoscore analysis showed higher numbers of moderately to severely inflamed areas in the hearts of CD69 Ϫ/Ϫ EAM mice compared with WT ( Figure  3B) . Accordingly, immunofluorescence analysis of myocardial sections in the acute phase of the disease revealed enhanced levels of platelet endothelial cell adhesion molecule-1/CD31 and CD68 ϩ macrophages and Gr-1 ϩ neutrophils in the hearts of CD69 Ϫ/Ϫ EAM mice ( Figure 3C and 3D ).
CD69
Ϫ/Ϫ mice developed a more exacerbated form of EAM than WT mice, with a significantly higher increase in the ratio of heart weight to body weight (HW/BW; Figure  4A ). Accordingly, hearts from CD69 Ϫ/Ϫ EAM mice were larger than those from WT animals ( Figure 4A , upper and lower). After the onset of inflammation, leukocytes and myocytes become apoptotic, and there was evidence of necrosis of cardiac muscle resulting in cardiac fibrosis. 32, 33 Masson trichrome staining in sections from the chronic phase of EAM scored as previously described 34 showed a significantly greater extent of myocardial fibrosis in CD69-deficient hearts compared with WT in the chronic phase of EAM ( Figure 4B and 4C ).
CD69 ؊/؊ Mice Exhibit Severe Ventricular Dysfunction
A pilot electrophysiological study with implantable telemetry revealed a 3-fold increase in the number of sinus pauses in EAM CD69 Ϫ/Ϫ mice compared with WT ( Figure 5A and data not shown). We then assessed cardiac function in the chronic phase of EAM in WT and CD69 Ϫ/Ϫ mice by transthoracic echocardiography. M-mode echocardiography of left ventricular function revealed a reduction in cardiac contractility in immunized CD69
Ϫ/Ϫ mice ( Figure 5B ). Both left ventricular fractional shortening and ejection fraction (EF) in CD69-deficient EAM mice were significantly diminished compared with immunized WT mice ( Figure 5C ). Analysis of B-mode EF distinguished groups of CD69 Ϫ/Ϫ mice with extensive myocarditis from the control group but could not discriminate the mild extension of myocarditis of WT EAM mice from the nonimmunized control group ( Figure 5D ). However, visual scoring detected significant differences between all groups (see the Methods section in the online-only Data Supplement). In comparison, B-mode EF measured by segmentation of the left ventricular endocardial edge in several planes has Ϫ/Ϫ mice in the chronic phase of EAM. C, Myocardial fibrosis was evaluated by histopathological microscopy of the percentage area of myocardium affected by fibrosis as described in the Methods section of the online-only Data Supplement. nϭ4; *PϽ0.02 (2-tailed Student t test).
the advantage of yielding objective data on global function (Movies I through IV in the online-only Data Supplement). Using this global disease severity score, we found that the absence of CD69 alters cardiac function and impairs heart contractility in EAM ( Figure 5E ).
Adoptive Transfer of Th17 Cells From CD69
؊/؊
EAM Mice Reproduces Exaggerated Inflammation in Nonimmunized WT Mice
We transferred exogenously differentiated Th17 cells from WT or CD69 Ϫ/Ϫ EAM mice into nonimmunized WT and CD69 Ϫ/Ϫ recipient mice ( Figure 6A ). Th17-polarized cell populations from WT and knockout mice contained similar proportions of IL-17 ϩ and IFN-␥ ϩ cells, and there were no differences in their expression levels of activation markers ( Figure III in the online-only Data Supplement).
Transthoracic echocardiography revealed a significant decrease in heart contractility in most of the mice tested on day 12 ( Figure IV in the online-only Data Supplement). Interestingly, we detected CD69-expressing cells within CD69 Ϫ/Ϫ mouse hearts, indicating that Th17 cells transferred from WT donors are able to migrate to the myocardium ( Figure 6B) . Moreover, the hearts of mice injected with CD69 Ϫ/Ϫ Th17 cells contained twice as many infiltrating neutrophils as the hearts of mice injected with WT Th17 cells ( Figure 6C ). These data demonstrate that CD69
Ϫ/Ϫ Th17 cells can induce an increase in heart infiltration independently of the genotype of the recipient.
To ascertain the role of CD69 expression on the lymphocyte compartment, we performed chimera experiments. Mice reconstituted with a mixture of BM from RAG2 Ϫ/Ϫ and CD69 Ϫ/Ϫ BM cells had a higher HW/BW ratio ( Figure 6D ) and larger number of infiltrating neutrophils ( Figure 6E ) than mice reconstituted with RAG2 Ϫ/Ϫ plus WT BM cells. Moreover, the increase in the disease parameters observed after reconstitution with RAG2 Ϫ/Ϫ plus CD69 Ϫ/Ϫ BM cells was independent of the genotype of the recipient mice. Therefore, these data unequivocally demonstrate that CD69 exerts its function within the lymphocyte compartment.
Discussion
In this study, we show that CD69 Ϫ/Ϫ mice develop a severe form of autoimmune myocarditis that progresses to DCM and heart failure. This pathogenic effect is exerted mainly through an increased Th17-mediated inflammatory response. Moreover, adoptive transfer of Th17 cells from immunized CD69 Ϫ/Ϫ mice and chimera experiments with RAG2 Ϫ/Ϫ and CD69 Ϫ/Ϫ BM cells reproduce severe myocardial inflammation in WT recipients, mimicking the phenotype observed in CD69 Ϫ/Ϫ mice immunized with MyHC-␣ peptide. Thus, our data indicate that CD69 is an important negative regulator of the pathogenesis and tissue damage observed in EAM. It is very feasible that a similar phenomenon occurs in humans with myocarditis and subsequent heart failure.
The involvement of Th17 lymphocytes in the pathogenesis of EAM has previously been documented. 12, 13 Hence, mice lacking T-bet, a T-box transcription factor essential for Th1 lineage differentiation, develop severe autoimmune myocarditis with an enhanced IL-17 production by heart-infiltrating lymphocytes. 12 Moreover, IFN-␥-deficient mice also develop a severe form of EAM that leads to DCM and heart failure. 15, 16, 35 In contrast, IL-12 receptor ␤1 Ϫ/Ϫ and STAT-4 Ϫ/Ϫ mice do not develop myocarditis, 11 indicating that IL-12 might be required for the development of the disease, although the p40 subunit of this receptor is shared with IL-23 and IL-12p40 -deficient mice are resistant to EAM. 13 Thus, all these data suggest that IL-23, rather than IL-12, is a determining factor in the development of myocarditis. IL-23 is also involved in the production of IL-17 and in the survival of Th17 cells. 36 Nevertheless, recent data indicate that IL-13 Ϫ/Ϫ mice develop severe myocarditis with low levels of IL-17 in the heart. In this setting, the severity of the disease might be a consequence of a compensatory enhancement in Th1 responses, resulting in high levels of IFN-␥, which, in turn, increase the population of classic macrophages and the levels of proinflammatory cytokines involved in the enhancement of the disease. 37 Thus, these data indicate that cytokines from both Th1 and Th17 cells are essential to the pathogenesis of EAM. 38 Remarkably, our data demonstrate that Th17 cells transferred from CD69 Ϫ/Ϫ mice into WT mice induced a stronger immune cell infiltrate in the myocardium, supporting the notion that CD69 acts as a regulator of heart inflammation and function. This is in accordance with the higher infiltration by neutrophils (CD11b ϩ Gr-1 ϩ ) and macrophages (F4/80 ϩ CD68 ϩ ) into hearts of CD69 Ϫ/Ϫ EAM mice. The immune response plays a critical role in host defense mechanisms, but an enhanced or persistent immune response or an autoimmune response elicited by exposure to cardiac antigens (eg, cardiac myosin and troponin I) can cause further damage to the heart. 1, 38, 39 High levels of proinflammatory cytokines can also activate inducible nitric oxide synthase in cardiac myocytes and macrophages, a phenomenon that has been associated with more intense inflammation and myocardial damage. 40 Other murine models of myocarditis indicate a link between acute and chronic inflammation of the myocardium and development of DCM and heart failure. 11, 16, 32 Both innate and adaptive immune responses have been implicated in immune-mediated heart damage, which determines the severity of myocarditis and the progression to DCM. 10,32,39 DCM is characterized by chronic ventricular dilatation with normal or reduced left ventricular wall thickness and deficient contraction. 4, 41 During the late stage of myocarditis, inflammation is replaced by reparative cardiac fibrosis and cardiac remodeling, resulting in cardiac dilatation and loss of contractile function of the heart. 33, 42 Consistent with this, our data show increased myocardial tissue fibrosis in the hearts of CD69 Ϫ/Ϫ mice compared with WT counterparts. Accordingly, hearts of CD69 Ϫ/Ϫ mice are enlarged compared with WT hearts and the HW/BW ratio of CD69 Ϫ/Ϫ mice is significantly increased.
Analysis of mouse ECGs has shown episodes of heart block that appear to be strain dependent. 43 Our electrophysiological study with implantable telemetry 44 revealed a higher number of sinus pauses in CD69 Ϫ/Ϫ mice than in WT animals, indicating that CD69 deficiency alters cardiac function. This finding is supported by our analysis of cardiac function by echocardiography, which identified a severe defect in left ventricular contractility in the chronic phase of EAM in CD69-deficient mice compared with the mild defect observed in WT mice. Together, our findings demonstrate an important role for CD69 in the control of the severity of myocarditis and subsequent DCM. Additional evidence that CD69 regulates inflammation through the control of Th17 immune responses is provided by the fact that EAM-induced Th17 cells from CD69 Ϫ/Ϫ mice adoptively transferred into nonimmunized WT mice reproduce the severity of the inflammation within the myocardium.
Conclusions
Our study supports an unexpected role for the leukocyte antigen CD69 as a brake on the progression and severity of autoimmune myocarditis and the development of DCM. In addition, our study paves the way to investigations into whether defects in CD69 expression or function influence the development of DCM in humans. These findings increase our knowledge of the development of myocarditis, providing a cellular and molecular basis for the development of novel specific therapies.
